Recall Record

Phoenix, AZ, United States

Central Admixture Pharmacy Services, Inc. recalls

8 recalls recorded since 2018, most recently on 16 July 2026. 3 are listed as ongoing. Status and classification are as published by the FDA.

Recalls8
Ongoing (FDA)3
Terminated or completed5
Class I (FDA)1

Ongoing Class III Drugs

Recall started
16 July 2026
Reason
Incorrect Product Formulation
Distribution
GA only
Initiated
Voluntary: Firm initiated
Recall number
D-0740-2026

Ongoing Class II Drugs

Recall started
2 June 2026
Reason
Incorrect product formulation: bag did not contain copper and famotidine per label.
Distribution
MA
Initiated
Voluntary: Firm initiated
Recall number
D-0618-2026

Ongoing Class I Drugs

Recall started
20 February 2025
Reason
Presence of Particulate Matter
Distribution
Product was distributed nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall number
D-0272-2025

Terminated Class II Drugs

Recall started
21 September 2023
Terminated
19 March 2025
Reason
Lack of assurance of sterility:
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0019-2024, D-0023-2024, D-0027-2024, D-0025-2024, D-0017-2024, D-0001-2024, D-0006-2024, D-0005-2024, D-0010-2024, D-0009-2024, D-0020-2024, D-0015-2024 and 20 more

Terminated Class II Drugs

Recall started
17 August 2023
Terminated
27 March 2025
Reason
Lack of Assurance of Sterility:Lack of validation data for sanitization cycles
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-1131-2023, D-1129-2023, D-1121-2023, D-1135-2023, D-1116-2023, D-1128-2023, D-1115-2023, D-1119-2023, D-1109-2023, D-1120-2023, D-1133-2023, D-1126-2023 and 20 more

Terminated Class II Drugs

Recall started
17 July 2023
Terminated
21 March 2025
Reason
Lack of assurance of sterility: Lack of validation data for sanitization cycles
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-1058-2023, D-1068-2023, D-1063-2023, D-1075-2023, D-1043-2023, D-1051-2023, D-1052-2023, D-1050-2023, D-1077-2023, D-1056-2023, D-1064-2023, D-1079-2023 and 27 more

Terminated Class II Drugs

Recall started
14 July 2023
Terminated
28 March 2025
Reason
Lack of assurance of sterility. Validation data for decontamination cycles is lacking.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-1002-2023, D-0968-2023, D-1032-2023, D-1012-2023, D-1001-2023, D-1022-2023, D-1024-2023, D-0962-2023, D-1003-2023, D-0964-2023, D-1036-2023, D-0992-2023 and 83 more

Terminated Class II Drugs

Recall started
28 April 2023
Terminated
22 June 2025
Reason
Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.
Distribution
Nationwide in the USA.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0747-2023, D-0667-2023, D-0684-2023, D-0655-2023, D-0750-2023, D-0723-2023, D-0738-2023, D-0678-2023, D-0728-2023, D-0743-2023, D-0700-2023, D-0696-2023 and 96 more

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.